The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | CMV reactivation during treatment with bispecifics for R/R myeloma
Eric Jurgens, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the prevalence of infections, particularly cytomegalovirus (CMV) reactivation, in patients with relapsed/refractory (R/R) multiple myeloma (MM) receiving bispecific antibody therapy. A single-center retrospective study demonstrated that 49% of patients exhibited detectable CMV, and 39% met the criteria for CMV reactivation. Despite this high rate, only a few patients required treatment, and no baseline characteristics or immune cell counts appeared to predict reactivation. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
